Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, explains the importance of up-to-date data when implementing medication therapy management programs.
Obtaining timely data and encouraging patient engagement are crucial to successful medication therapy management programs, said Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare.
Transcript
Are different demographics more susceptible to the effects of cytochrome P450 (CYP450) enzymes?
So everybody is different and everybody can have a different response to medications based on their genetic differences. So race and ethnicity can play a role in adverse drug events. You know, some people may be ultra metabolizers. Some may be poor metabolizers. And ultimately that's going to affect the way that they process those medications.
If medication therapy management (MTM) programs help with these issues, what are some of the barriers payers face in implementing these programs?
I think some of the biggest barriers to implementing real successful MTM programs are timely data. So you want to make sure that when you're speaking to a patient that you have the most up to date information for that patient that allows you to have more impactful interventions or recommendations with that patient, but also patient engagement. So one, how can you get ahold of this patient to talk to them about their medications and establishing that trust with the patient, that you are a clinician calling on their behalf and that you do want to help them? Make sure that they are on the most safe medications and really getting optimal use from the medications that they're taking.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Can Medicare Sustain Widespread Access to GLP-1 Therapies?
April 25th 2025Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More